Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c

Go back to Sangamo Biosciences (SGMO) Misses Q2 EPS by 4c

Sangamo BioSciences Reports Second Quarter 2015 Financial Results

August 5, 2015 4:02 PM EDT

RICHMOND, Calif., Aug. 5, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its second quarter 2015 financial results and accomplishments.

For the second quarter ended June 30, 2015, Sangamo reported a consolidated net loss of $12.1 million, or $0.17 per share, compared to a net loss of $7.0 million, or $0.10 per share, for the same period in 2014. As of June 30, 2015, the Company had cash, cash equivalents, marketable securities and interest receivable of $218.6 million.

Revenues for the second quarter of 2015 were $8.4 million, compared to $10.4 million for the same... More

Sangamo BioSciences Announces Presentation At The 2015 Wedbush Pacgrow Healthcare Conference

August 4, 2015 4:02 PM EDT

RICHMOND, Calif., Aug. 4, 2015 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today that Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:35am ET on Tuesday, August 11, 2015, at the 2015 Wedbush Pacgrow Healthcare Conference. The... More